Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I1ZY
|
|||
| Former ID |
DIB006474
|
|||
| Drug Name |
Tralokinumab
|
|||
| Synonyms |
CAT-354; Anti-IL 13 monoclonal antibody, CAT/AstraZeneca; IL-13 antagonist, CAT/AstraZeneca; Interleukin-13 antagonist, CAT/AstraZeneca
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Atopic dermatitis [ICD-11: EA80; ICD-10: L20] | Approved | [1] | |
| Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 3 | [2], [3] | ||
| Asthma [ICD-11: CA23; ICD-10: J45, J45.8] | Phase 1/2 | [4], [5], [6], [7], [8], [9], [10], [11] | ||
| Company |
LEO Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-13 (IL13) | Target Info | Inhibitor | [12] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| Fc epsilon RI signaling pathway | ||||
| Measles | ||||
| Asthma | ||||
| Inflammatory bowel disease (IBD) | ||||
| NetPath Pathway | IL9 Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Leptin Signaling Pathway | ||||
| TSLP Signaling Pathway | ||||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathwhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | |||
| Pathway Interaction Database | Glucocorticoid receptor regulatory network | |||
| IL12 signaling mediated by STAT4 | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Cytokines and Inflammatory Response | ||||
| Allograft Rejection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761180. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8001). | |||
| REF 3 | ClinicalTrials.gov (NCT02281357) Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With Oral Corticosteroid Dependent Asthma. U.S. National Institutes of Health. | |||
| REF 4 | ClinicalTrials.gov (NCT02085473) A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Tralokinumab When Delivered at Different Flow Rates to Healthy Volunteers | |||
| REF 5 | ClinicalTrials.gov (NCT01592396) A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma | |||
| REF 6 | ClinicalTrials.gov (NCT01629667) A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis | |||
| REF 7 | ClinicalTrials.gov (NCT02449473) Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids | |||
| REF 8 | ClinicalTrials.gov (NCT02684097) A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata | |||
| REF 9 | ClinicalTrials.gov (NCT01482884) Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis | |||
| REF 10 | ClinicalTrials.gov (NCT01402986) A Safety and Efficacy Study of Tralokinumab in Adults With Asthma | |||
| REF 11 | ClinicalTrials.gov (NCT02347176) Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis | |||
| REF 12 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.